康泰医学(300869) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥122,095,483.51, a decrease of 0.53% compared to the same period last year, and a year-to-date revenue of ¥333,885,288.03, down 45.91% year-on-year [1]. - The net profit attributable to shareholders for Q3 2024 was ¥1,735,807.07, representing an 85.81% decline year-on-year, with a year-to-date net profit of ¥9,902,927.86, down 94.92% compared to the previous year [1]. - Total operating revenue for Q3 2024 was ¥333,885,288.03, a decrease of 46.0% compared to ¥617,227,119.11 in Q3 2023 [13]. - Net profit for Q3 2024 was ¥9,902,927.86, down 94.9% from ¥195,117,554.43 in the same period last year [14]. - The total comprehensive income for Q3 2024 was ¥9,189,073.07, down from ¥196,449,750.31 in Q3 2023, a decline of 95.3% [15]. - Basic earnings per share for Q3 2024 were ¥0.0246, a decrease of 94.9% from ¥0.4856 in the previous year [15]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥35,193,005.23, a significant decrease of 80.20% compared to the same period last year [5]. - The net cash flow from operating activities for Q3 2024 was ¥35,193,005.23, a decrease of 80.24% compared to ¥177,722,313.98 in Q3 2023 [17]. - The cash paid for operating activities was ¥327,640,769.58, a reduction of 50.49% from ¥660,538,460.96 in the previous year [17]. - The company reported a net cash flow from investing activities of ¥408,315,248.82, a turnaround from a negative cash flow of ¥717,018,969.77 in the same period last year, due to cash management from convertible bonds [5]. - The total cash inflow from investment activities reached ¥4,377,891,221.28, significantly up from ¥121,754,759.57 in the previous year [17]. - The cash outflow from financing activities totaled ¥476,682,802.77, down from ¥1,244,315,368.57 in the same quarter last year [17]. - The company reported a net decrease in cash flow from financing activities of ¥386,682,802.77, an improvement compared to a decrease of ¥491,943,768.13 in Q3 2023 [17]. Assets and Liabilities - The company's total assets as of September 30, 2024, were ¥2,832,593,222.54, reflecting an 11.81% decrease from the end of the previous year [1]. - Total current assets decreased to ¥1,851,736,075.88 from ¥2,482,164,235.52, a decline of about 25.4% [10]. - Non-current assets increased to ¥980,857,146.66 from ¥729,782,416.65, reflecting an increase of approximately 34.3% [11]. - Total liabilities decreased to ¥899,145,607.46 from ¥1,167,149,962.89, a reduction of 23.0% year-over-year [13]. - The company's total equity as of Q3 2024 was ¥1,933,447,615.08, down from ¥2,044,796,689.28, reflecting a decline of 5.4% [13]. - Short-term borrowings decreased significantly from ¥347,000,000.00 to ¥90,000,000.00, a decrease of approximately 74.0% [11]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 35,014 [6]. - The largest shareholder, Hu Kun, holds 46.84% of the shares, totaling 188,189,252 shares [6]. Other Financial Metrics - The company's cash and cash equivalents increased to ¥602,394,001.29 from ¥470,525,587.01, representing a growth of approximately 28.8% [10]. - The company reported a significant increase in other receivables by 117.22% to ¥15,408,410.61, primarily due to interest guarantees for transferable large-denomination certificates of deposit [4]. - The company experienced a 77.78% decrease in non-current assets due within one year, amounting to ¥163,935,069.48, mainly due to a reduction in time deposits maturing within one year [4]. - Investment income for the year-to-date period was ¥15,360,687.14, down 73.10% year-on-year, attributed to the expiration of forward foreign exchange contracts from the previous year [4]. - The company recorded a significant increase in other income by 218.34% to ¥1,376,087.09, mainly from increased income from the sale of scrap materials [4]. - Research and development expenses for Q3 2024 were ¥83,429,418.51, an increase of 4.0% compared to ¥79,806,439.64 in Q3 2023 [14]. - The financial expenses for Q3 2024 showed a significant improvement, with a net income of -¥3,681,104.46 compared to -¥31,354,673.38 in Q3 2023 [14]. - The cash received from investment income was ¥97,261,221.84, up from ¥55,690,364.33 in Q3 2023, indicating a growth of 74.73% [17]. - The cash paid for taxes was ¥39,173,430.22, a decrease of 42.94% compared to ¥68,622,374.83 in the same quarter last year [17]. - The company experienced a foreign exchange impact on cash and cash equivalents of -¥5,475,666.14 in Q3 2024, contrasting with a positive impact of ¥6,881,813.01 in Q3 2023 [18].